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The expression of the proto-oncogene c-myc is frequently deregulated, via multiple mechanisms, in human breast cancers.
Deregulated expression of c-myc contributes to mammary epithelial cell transformation and is causally involved in mammary
tumorigenesis in MMTV-c-myc transgenic mice. c-Myc is known to promote cellular proliferation, apoptosis, genomic instability and
tumorigenesis in several distinct tissues, both in vivo and in vitro. Expression of the proapoptotic regulatory gene bax is reduced or
absent in human breast cancers, and c-Myc has been shown to regulate the expression of Bax, as well as cooperate with Bax in
controlling apoptosis in a fibroblast model. Additionally, loss of bax reduces c-Myc-induced apoptosis in lymphoid cells and increases
c-Myc-mediated lymphomagenesis in vivo. In order to assess whether loss of bax could influence c-Myc-induced apoptosis and
tumorigenesis in the mammary gland in vivo, we generated MMTV-c-myc transgenic mice in which neither, one, or both wild-type
alleles of bax were eliminated. Haploid loss of bax in MMTV-c-myc transgenic mice resulted in significantly reduced mammary tumour
apoptosis. As anticipated for an apoptosis-regulatory gene, loss of the wild-type bax alleles did not significantly alter cellular
proliferation in either mammary adenocarcinomas or dysplastic mammary tissues. However, in contrast to c-Myc-mediated
lymphomagenesis, loss of one or both alleles of bax in MMTV-c-myc transgenic mice did not significantly enhance mammary
tumorigenesis, despite evidence that haploid loss of bax might modestly increase mammary tumour multiplicity. Our results
demonstrate that Bax contributes significantly to c-Myc-induced apoptosis in mammary tumours. In addition, they suggest that in
contrast to c-Myc-induced lymphomagenesis, mammary tumorigenesis induced by deregulated c-myc expression requires some
amount of Bax expression.
British Journal of Cancer (2004) 91, 1372–1379. doi:10.1038/sj.bjc.6602137 www.bjcancer.com
Published online 31 August 2004
& 2004 Cancer Research UK
Keywords: Bax; c-Myc; transgenic mice; mammary gland; apoptosis; tumorigenesis
                                                         
The proto-oncogene c-myc was first identified as the mammalian
homologue of the viral transforming oncogene, v-myc, responsible
for avian myelocytomatosis (Vennstrom et al, 1982). c-Myc
is a DNA-binding, nuclear transcription factor involved in the
regulation of cell cycle progression, programmed cell death,
cellular metabolism, and differentiation (Evan and Littlewood,
1993; Harrington et al, 1994; Packham and Cleveland, 1995).
In 1994, the Dual Signal model proposed that induction of
apoptosis, a potent mechanism for the suppression of tumorigen-
esis, was an obligate function of deregulated c-myc expression;
however, more recent experimentation suggests that c-Myc
may sensitise cells to apoptosis as a result of alterations in
mitochondrial membrane permeability and movement of holocy-
tochrome c into the cytoplasm from its typical position as a
constituent of the electron transport system (Juin et al, 1999;
Prendergast, 1999). Experiments examining the cooperation of c-
Myc and knockouts of p19
ARF and/or p53 in mouse embryo
fibroblast models have suggested that suppression of c-Myc-
induced apoptosis may facilitate malignant transformation and
tumorigenesis (Zindy et al, 1998). c-Myc may increase genomic
instability and enhance tumorigenesis without an absolute
requirement for continued aberrant c-myc expression once
additional transforming genetic lesions have been generated and
fixed in the genome (Felsher and Bishop, 1999a,b). Deregulated or
aberrant expression of c-myc, via mechanisms including translo-
cation, proviral insertion, locus amplification, point mutation,
direct transcriptional and translational effects, or post-transla-
tional modifications, is a signature of several different human
tumour types and c-myc can induce tumorigenesis under
conditions where programmed cell death is abrogated (Evan et al,
1992; Santoni-Rugiu et al, 1998; Dang, 1999). The relevance of
aberrant c-myc expression to the pathogenesis of breast cancer is
confirmed by the finding that the c-myc locus is rearranged in
roughly 5%, amplified in 16%, and overexpressed in approximately
70% of human breast tumours (Nass and Dickson, 1997; Deming
et al, 2000).
The role of c-myc expression in normal mammary gland
development and function as well as mammary tumorigenesis is
a burgeoning field of inquiry. Several in vitro studies have
Received 4 February 2004; revised 16 July 2004; accepted 23 July 2004;
published online 31 August 2004
*Correspondence: Dr RB Dickson; E-mail: DicksonR@georgetown.edu
British Journal of Cancer (2004) 91, 1372–1379
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sdemonstrated a contributory role for c-Myc in transformation of
both human and murine mammary epithelial cells (MECs) (Leder
et al, 1986; Telang et al, 1990; Valverius et al, 1990). Examination
of normal murine mammary development has indicated that
c-Myc is expressed during pregnancy-associated proliferation and
postlactational involution associated MEC apoptosis (Strange et al,
1992). To further evaluate the role of c-Myc in mammary
development, function, and transformation, a transgenic mouse
was generated expressing the murine c-myc gene under the control
of the mouse mammary tumour virus long terminal repeat
(MMTV-LTR) promotional elements (Stewart et al, 1984).
MMTV-c-myc transgenic mice develop mammary adenocarcino-
mas in both the virgin state (B50% incidence following a 7–14
month latency) and the multiparous state (B100% incidence with
two or more pregnancies); however, the extended mammary
tumour latencies and low mammary tumour multiplicities suggest
that c-myc is contributory to but insufficient for mammary
tumorigenesis in the mouse (Stewart et al, 1984; Leder et al, 1986).
The conditional expression of c-myc in the mammary glands of
mice using an MMTV-LTR-driven tetracycline-responsive trans-
genic system has provided evidence for cooperative, transforming
genetic alterations that may result from c-Myc-induced genomic
instability (D’Cruz et al, 2001). Furthermore, the use of spectral
karyotyping (SKY) and comparative genomic hybridisation (CGH)
to demonstrate that MMTV-c-myc-induced mammary tumours
display distinct, repeatable patterns of chromosomal alterations
suggests that c-Myc may exert a dominant genomic mutator effect
and that specific genetic lesions may cooperate in MEC
transformation (reflecting the multistage nature of human
tumorigenesis) (Weaver et al, 1999).
TGFa, a soluble growth factor of the epidermal growth factor
family of ligands, is a potent survival and growth factor for human
and murine MECs both in vivo and in vitro, and when
overexpressed in the mammary glands of transgenic mice, induces
mammary alveolar hyperplasias and occasional mammary adeno-
carcinomas (Bates et al, 1990; Jhappan et al, 1990; Matsui et al,
1990; Sandgren et al, 1990; Snedeker et al, 1991; Amundadottir
et al, 1995). The prosurvival molecule Bcl-2 has been shown to be
expressed in the normal human and murine mammary epithelium,
to impede mammary gland involution when expressed as an
exogenous transgene, and to suppress c-myc-induced apoptosis
and cooperate with c-myc expression in inducing B-cell malig-
nancies in another transgenic model (Bargou et al, 1995; Schorr
et al, 1999a,b; Feuerhake et al, 2000; Eischen et al, 2001b). The
importance of suppression of apoptosis in c-myc-induced murine
mammary tumorigenesis has been suggested by three indepen-
dently generated transgenic mouse models: MMTV-c-myc/
MT-tgfa, WAP-c-myc/WAP-tgfa, and MMTV-c-myc/WAP-bcl2
(Amundadottir et al, 1995; Sandgren et al, 1995; Ja ¨ger et al,
1997). Data from these three mammary bitransgenic studies
strongly suggest that mammary tumorigenesis is significantly
enhanced when deregulated c-myc expression, responsible for
driving both proliferation and apoptosis, is coupled with altera-
tions that block c-myc-mediated apoptotic pathways.
Bax, a proapoptotic member of the Bcl-2 family of proteins, was
first discovered in a screen of proteins that exhibited binding
interactions with Bcl-2 (Oltvai et al, 1993). Bax is likely to have
pore-forming activity in the mitochondrial membranes, subject to
control or prevention by association with specific antiapoptotic
molecules (especially Bcl-2 and Bcl-xL), related to its ability to bind
to BH-3 domain-only containing Bcl-2 family member proteins,
and induce the release of mitochondrial cytochrome c (Antonsson
et al, 1997; Jurgensmeier et al, 1998; Desagher et al, 1999; Murphy
et al, 1999; Antonsson et al, 2000; Nouraini et al, 2000; Wei et al,
2001). Bax is weakly expressed or absent in several breast cancer
cell lines and transfection of bax into these lines results in
increased apoptotic sensitivity and diminished tumour prolifera-
tion in athymic mice (Bargou et al, 1995, 1996; Sakakura et al,
1996). Bax is expressed in the epithelium of the normal breast and
its expression is highest during postlactational mammary gland
involution; furthermore, Bax expression is significantly reduced or
absent in invasive ductal breast carcinomas (Krajewski et al, 1994;
Bargou et al, 1995; Li et al, 1996; Feuerhake et al, 2000; Shilkaitis
et al, 2000). Significant reductions in Bax expression were found in
34% of primary breast tumours in women with metastatic disease,
Bax expression was inversely correlated with overall survival,
treatment response, and metastasis in these patients, and Bax
expression was found to be predictive of tumour response to
chemotherapy independent of other predictive variables (Krajews-
ki et al, 1995; Kapranos et al, 1997; Sjo ¨stro ¨m et al, 1998).
The mechanisms by which c-Myc induces apoptosis and the
manner in which this apoptosis contributes to tumour suppression
are largely unknown and currently being explored. Recently, bax
was determined to be transcriptionally regulated by c-Myc in a
variety of human cell lines (including the SkBr3 human breast
cancer cell line) and found to be critical for the induction of
apoptosis by aberrant c-Myc expression in a mouse embryo
fibroblast model system (Mitchell et al, 2000). Two other studies
indicate that c-Myc, at least in embryo fibroblast systems, activates
a proapoptotic function in Bax and induces an apoptotic program
that requires Bax (or a BH3 domain peptide) to be present in the
mitochondrial membrane (Soucie et al, 2001; Juin et al, 2002). In
addition, bax-deficient primary pre-b cells have been shown to be
resistant to proapoptotic effects of c-Myc. Furthermore, in a
transgenic mouse model, loss of one or both bax allele(s)
significantly accelerate c-Myc-dependent lyphomagenesis in a
bax gene dosage-dependent manner (Eischen et al, 2001a). The
partial or total loss of bax in knockout mice provides evidence that
the presence of Bax is unlikely to be required for mammary gland
development and secretory differentiation (a very small percentage
of bax-nullizygous mice did evidence postpartum lactational
incompetency); however, loss of bax did reduce MEC apoptosis
during postlactational involution (Knudson et al, 1995; Schorr et al,
1999a,b). Loss of bax (reflecting the in vivo situation of human
breast cancer patients) may disrupt c-Myc-induced apoptotic
programs in mammary epithelial cells and has the potential to
diminish the tumour suppressive activity of c-Myc-induced
apoptosis. In this study, we have generated a combinatorial,
mammary-relevant transgenic model, bax-knockout/MMTV-c-myc
transgenic, to examine the influence of allelic bax loss on c-Myc-
induced apoptosis and tumorigenesis in vivo.
MATERIALS AND METHODS
Transgenic and knockout mice
All animal experiments were conducted in accordance with US and
UK CCR guidelines (Workman et al, 1998) and in accordance
with our institutionally approved protocol. MMTV-c-myc trans-
genic mice (FVB inbred genetic background) were obtained
from Charles River Laboratories, bred under a license from
DuPont Medical Products, and housed as previously described
(Amundadottir et al, 1995). The MMTV-c-myc transgenic mice
contain a mouse mammary tumour virus long terminal repeat
promoter element driving the expression of a murine c-myc gene
(Stewart et al, 1984). Mice hemizygous for bax (C57BL/6 inbred
genetic background) were obtained from SJ Korsmeyer via PA
Furth at Georgetown University (Knudson et al, 1995). P
generation myc mice were bred to P generation bax-hemizygous
mice and subsequently, their F1 generation offspring were back-
crossed with P generation bax-hemizygous mice, resulting in F2
generation offspring in which the myc transgene was found in the
context of no, one, or two intact wild-type bax alleles. All data
reported herein were generated using F2 generation study mice on
the mixed genetic background (C57BL/6 FVB; 3:1). Parous
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sstudy mice, 10 weeks old, were housed with males and repetitively
bred until euthanisation; all surviving pups were weaned at day 20
postpartum. Female parous study mice were examined bi-weekly
for tumours and morbidity and euthanased if they showed signs of
ill health using approved methods (Workman et al, 1998).
Genotyping
Overnight digestion of mouse tail biopsy samples (Workman et al,
1998) in STE buffer (0.1 M NaCl, 0.05 M Tris pH 8.0, 1mM EDTA,
and 1% SDS) containing 5mgml
 1 fungal proteinase K (Invitro-
gen, Carlsbad, CA, USA), followed by phenol/chloroform extrac-
tion and ethanol precipitation yielded genomic DNA subsequently
used in genotyping of all mice utilised in this study. PCR-based
genotyping was performed on a Stratagene Robocycler Gradient 40
machine using tail-derived genomic DNA, sequence-specific
primers, and Platinum PCR Supermix (Invitrogen). MTVMyc50
primer (50-CCC AAG GCT TAA GTA AGT TTT TGG-30) and
MTVMyc30 primer (50-GGG CAT AAG CAC AGA TAA AAC ACT-
30) were used to identify MMTV-c-myc transgenic mice (1min
denaturation at 951C, 1min annealing at 521C, and 75s elongation
at 721C for a total of 42 cycles); transgene-positive animals were
identified by resolution of a single B880bp band on a 1.0%
agarose gel. BPR2 primer (50-GTT GAC CAG AGT GGC GTA GG-
30), MK1 primer (50-GAG CTG ATC AGA ACC ATC ATG-30), and
NRP2 primer (50-CCG CTT CCA TTG CTC AGC GG-30) were used
to determine the allelic status of bax (45s denaturation at 941C,
90s annealing at 551C, and 2min elongation at 721C for a total of
35 cycles); animals with bax in the wild-type configuration
demonstrate a single B300bp band, animals nullizygous for bax
demonstrate a single B506bp band, and animals hemizygous for
bax demonstrate both bands on a 1.0% agarose gel.
Mammary gland tumour collection, histopathology, and
whole-mount preparation
Mammary gland tumours and tissues were freshly collected via
routine dissection procedures and split for fixation, liquid N2
snap-freezing (for molecular analyses), and whole-mount prepara-
tion. Mammary gland tumours and tissues were fixed in 10%
neutral-buffered formalin (EM Sciences, Gibbstown, NJ, USA) in
phosphate-buffered saline (PBS), embedded in paraffin, and
sectioned by microtomy to 5mM. Mammary tumour and tissue
sections were stained using haematoxylin and eosin and were
subjected to histopathological evaluation using light microscopy.
Mammary gland tissues for whole-mount preparation, routinely
taken from the inguinal glands unless otherwise tumour involved,
were fixed in 75% ethanol/25% glacial acetic acid, stained in a 0.2%
carmine alum (Sigma, St Louis, MO, USA)/0.5% aluminum
potassium sulfate solution, dehydrated through an ethanol series,
cleared in toluene, mounted using Permount (Fisher, Fair Lawn,
NJ, USA), and examined using dissecting stereomicroscopy.
Western blot analyses
Mammary gland tumour and tissue samples that were harvested
from the study mice were immediately snap-frozen in liquid N2,
stored at  801C, and later thawed in a RIPA homogenisation
solution ( 1 PBS containing 1% NP-40, 0.5% sodium-deoxycho-
late, 0.1% SDS, and 10mgml
 1 PMSF). Briefly, samples were
weighed, ground into a fine powder under liquid N2, lysed for
15min on ice in a five-fold volume of RIPA solution, and
centrifuged at B10000g for 15min at 41C. Supernatants were
recovered after high-speed centrifugation and subject to protein
concentration quantification via BCA Protein Assay (Pierce,
Rockland, IL, USA). Protein lysates were then combined with
 4 Laemmli Sample buffer (final concentration 50mM Tris-HCl
pH 6.8, 100mM dithiothreitol, 10% glycerol, 0.1% bromophenol
blue, 2% SDS), boiled for 10min, fractionated through 12% Tris-
glycine gels (Invitrogen) under reducing conditions, transferred
onto Immobilon-P membranes (Millipore, Bedford, MA, USA),
and blocked in 1  PBS containing 5% milk and either 0.3%
Tween-20 for c-Myc detection or 0.05% Tween-20 for Bax
detection. For Western analysis, blots were incubated for 1h at
room temperature with anti-c-Myc (C-19) or anti-Bax (N-20)
antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
washed repeatedly, and incubated in horseradish peroxidase
(HRP)-conjugated secondary antibodies (NA934 from Amersham,
Buckinghamshire, UK or 611-1302 from Rockland, Gilbertsville,
PA, USA for c-Myc; SC-2004 from Santa Cruz). Protein visualisa-
tion was achieved using the ECL Western Blotting Reagent Kit
(Amersham) and Hyperfilm-ECL photographic film (Amersham).
Apoptosis and cell proliferation assays
Formalin-fixed, paraffin-embedded mammary tumours were sec-
tioned by microtomy and subsequently utilised to assess the
presence and extent of apoptosis in the tumours and surrounding
mammary tissues. The terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick end-labeling (TUNEL) method was
used to evaluate apoptosis in these sections (ApopTag Peroxidase
In situ Apoptosis Detection Kit, Serologicals, Norcross, GA, USA).
Briefly, sections were cleared in xylene, rehydrated through an
ethanol series, treated with Autozyme Digestion reagent (Biomeda,
Foster City, CA, USA), and quenched in 0.15% H2O2 (Sigma). The
TdT reaction was allowed to proceed at room temperature, under
humidified conditions, for 40min and a peroxidase-conjugated
anti-digoxigenin antibody was used to assess digoxigenin-dUTP
incorporation. A diaminobenzidine/urea chromogen substrate
system (Sigma) was used to visualise the TUNEL labeling reaction.
Sections were counterstained in 0.5% methyl green dye (Trevigen,
Gaithersburg, MD, USA), washed in 100% butanol, and mounted
using DPX mountant (Electron Microscopy Sciences). Histological
assessment of apoptosis, leading to the calculation of apoptotic
index values, was conducted by counting the number of TUNEL-
positive apoptotic cells out of 41000 cells in contiguous high-
powered ( 40) fields.
Formalin-fixed, paraffin-embedded mammary tumours were
sectioned by microtomy, stained with haematoxylin, and utilised
to assess the presence and extent of cell proliferation in the
tumours and surrounding mammary tissues. Histological assess-
ment of cell proliferation, leading to the calculation of mitotic
index values, was conducted by counting the number of mitotic
figures out of 41000 cells in contiguous high-powered ( 40)
fields.
Statistical analyses
To evaluate the significance of differences in tumour apoptosis and
proliferation between genotypes, all data were subjected to analysis
of variance (ANOVA) and Scheffe post hoc testing. A Kaplan–
Meier curve was generated for the tumour incidence data for the
parous study mice and tumour incidence differences between
genotypes were assessed using a generalised Wilcoxon test.
Analysis of variance testing was utilised to evaluate the significance
of tumour multiplicity differences between genotypes.
RESULTS
Loss of allelic bax alters mammary tumour multiplicity in
parous MMTV-c-myc transgenic mice
In order to assess the influence of loss of allelic bax on c-Myc-
induced apoptosis and tumorigenesis in the mammary gland, 10—
week-old female study mice (myc baxþ/þ, n¼10; myc baxþ/ ,
n¼9; myc bax / , n¼10) were housed with male mice, bred
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srepetitively, and followed bi-weekly for evidence of mammary
tumour development. Parous study mice were euthanised when
mammary tumour burden approached 10% of animal body mass
or when mice reached 1 year of age (in accordance with US and
UKCCR guidelines, Workman et al, 1998). Loss of one wild-type
bax allele in parous c-myc transgenic mice elevated mammary
tumour multiplicity (2.75 tumours/mouse vs 1 tumour/mouse; P
 0.04 by ANOVA) as compared to parous c-myc transgenic mice
in which bax was intact or completely eliminated (Figure 1A). A
nonsignificant trend towards increased mammary tumour inci-
dence was found for parous MMTV-c-myc transgenic/bax-hemi-
zygous mice (44.4 vs 20 and 20%; P¼0.39 by Wilcoxon) as
compared to parous c-myc transgenic mice in which bax was intact
or completely eliminated (Figure 1B). Mammary tumour latency
and parity at time of mammary tumour development were not
altered by loss of allelic bax in parous MMTV-c-myc transgenic
mice (data not shown).
Mammary gland whole-mount and haematoxylin and eosin-
stained tissue sections were examined for evidence of mammary
histopathology. Assessment of mammary gland whole-mounts
demonstrated that hyperplastic alveolar nodular changes were
present only in mammary glands from tumour-bearing, c-myc
transgene-positive study mice and were not qualitatively different
with loss of allelic bax (data not shown). Microscopic histopatho-
logical assessment of the sections indicated that the mammary
tumours that developed in the parous MMTV-c-myc study mice
were cribiform glandular adenocarcinomas as previously described
for MMTV-c-myc mammary tumours (Cardiff et al, 2000).
Furthermore, loss of allelic bax, in parous MMTV-c-myc study
mice, did not alter the histopathological character of these
mammary tumours nor of the peri-tumorous dysplastic mammary
lesions (data not shown).
c-Myc and Bax expression in mammary tumours and tissue
from parous MMTV-c-myc transgenic mice
The incidence of mammary tumours in MMTV-c-myc transgenic
mice, on the FVB inbred genetic background, has been reported to
be approximately 50% for virgin female mice and approaching
100% for multiparous female mice (Stewart et al, 1984; Amunda-
dottir et al, 1995). The overall mammary tumour incidence for
multistrain (C57BL/6 FVB; 3:1), multiparous, c-myc transgene-
positive study mice were 27.6%, considerably lower than
previously reported. Western blot analysis was utilised to
determine the expression status of the MMTV-c-myc transgene
in the mammary tumours and mammary gland tissue from parous
study mice (c-myc transgene-negative mice were included as an
assay negative control). c-Myc protein expression was only
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Figure 1 Loss of bax influences mammary tumour multiplicity but not
mammary tumour incidence in parous MMTV-c-myc transgenic/bax-
knockout mice. (A) Mammary tumour multiplicity was increased in parous
MMTV-c-myc/bax-hemizygous transgenic mice (*P¼0.04 by ANOVA).
(B) Kaplan–Meier analysis by genotype demonstrates a nonsignificant
trend toward decreased tumour-free incidence with bax-hemizygosity in
parous MMTV-c-myc transgenic/bax-knockout mice (P¼0.39 by general-
ised Wilcoxon testing).
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Figure 2 Western blot analysis of transgenic c-Myc protein expression
and Bax protein expression in mammary tumours and mammary gland
tissues from parous MMTV-c-myc transgenic/bax-knockout mice. Protein
lysates were prepared from mammary tumours (T lanes), mammary gland
tissues (MG lanes), and from the A-20 murine lymphoblast cell line (Bax
protein positive control). (A) Western blot analysis demonstrates
expression of c-Myc protein only in mammary tumour lysates from c-
myc transgene-positive parous study mice. (B) Western blot analysis
demonstrates that expression of Bax protein is lost in tumour and
mammary gland tissue lysates from bax-nullizygous parous study mice, that
expression of Bax protein is reduced in mammary gland tissue lysates from
bax-hemizygous parous study mice as compared with bax-intact mice, and
confirms that bax loss of heterozygosity is not evident in mammary
tumours from parous MMTV-c-myc transgenic/bax-hemizygous study mice
(Western blots were run simultaneously under identical conditions with
mammary gland tissue lysates equally loaded for the amount of protein).
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sdetectable in lysates from mammary adenocarcinomas and not in
lysates from nontumorous mammary gland tissue from c-myc
transgene-positive mice (Figure 2A and data not shown).
Western blot analysis confirmed that Bax protein expression
was absent in mammary tumour and mammary gland tissue
lysates from parous study mice nullizygous for bax (Figure 2B).
Western blot analysis also confirmed that Bax protein expression
was reduced in mammary gland tissue lysates (equally loaded for
protein and run simultaneously under identical conditions)
prepared from bax-hemizygous parous study mice as compared
to bax-intact parous study mice (Figure 2B). Loss of heterozygosity
(LOH) for bax was not found to be a part of mammary tumour
development and progression in the C3(1)/SV40-Tag transgenic/
bax-hemizygous murine tumour model (Shibata et al, 1999) nor in
malignancies arising in arf-nullizygous/bax-hemizygous mice
(Eischen et al, 2002). Bax LOH was not found in mammary
tumour development in parous MMTV-c-myc transgenic/bax-
hemizygous mice (Figure 2B and data not shown).
Loss of allelic bax significantly diminishes mammary
tumour apoptosis in parous MMTV-c-myc transgenic mice
Apoptotic indices were generated for both mammary adenocarci-
nomas and peri-tumorous dysplastic lesions by counting TUNEL-
positive cell on mammary tumour and tissue sections. As shown in
Figure 3, apoptosis was significantly decreased in mammary
adenocarcinomas with loss of allelic bax in parous MMTV-c-myc
study mice (9.0571.12 for myc baxþ/þ vs 7.3870.17 for myc
baxþ/  vs 5.4870.28 for myc bax / ); furthermore, a trend
toward diminished apoptosis was seen in mammary dysplastic
lesions with loss of allelic bax in parous MMTV-c-myc study mice
(7.2071.30 for myc baxþ/þ vs 4.1770.50 for myc baxþ/  vs
2.2970.71 for myc bax / ). In mammary adenocarcinomas, the
levels of apoptosis were significantly different for each of the three
evaluated genotypes (P¼0.001 for myc baxþ/þ vs myc baxþ/ ;
P¼0.033 for myc baxþ/  vs myc bax / ; and P¼0.017 for myc
baxþ/þ vs myc bax / ) as well as between the adenocarcinomas
and dysplastic mammary lesions in tumour-bearing, parous
MMTV-c-myc/bax-hemizygous study mice (P¼0.001).
Loss of allelic bax does not alter cellular proliferation in
mammary tumours from parous MMTV-c-myc transgenic
mice
Proliferative indices were generated for both mammary adenocarci-
nomas and peritumorous dysplastic lesions by counting mitotic
figures on mammary tumour and tissue sections. As shown in
Figure 4, proliferation was not significantly altered in either
mammary adenocarcinomas or dysplastic mammary lesions with
loss of allelic bax in parous MMTV-c-myc study mice. Within each
genotype, there was significantly more cellular proliferation in
mammary adenocarcinomas as compared with peritumorous
dysplastic mammary lesions (2.0370.58 vs 0.4970.005 for myc
baxþ/þ, P¼0.048; 1.5570.17 vs 0.2370.05 for myc baxþ/ ,
P¼0.024; and 1.6070.06 vs 0.2070.09 for myc bax / , P¼0.0001).
DISCUSSION
The exogenous expression of murine c-myc using the MMTV-LTR
promoter system has previously been demonstrated to induce
mammary tumorigenesis; furthermore, these mammary tumours
are characterised by a significantly elevated apoptotic index
(Stewart et al, 1984; Amundadottir et al, 1996). Results from the
MMTV-c-myc/MT-tgfa bitransgenic mammary tumour model
suggest that a diminution of in vivo apoptosis can accentuate c-
Myc-induced mammary tumour formation (Amundadottir et al,
1995). The Bax protein is known to be a key mitochondrial
regulator of apoptosis and has been shown to be a transcriptional
target of c-Myc (Mitchell et al, 2000). In this latter capacity, Bax
may be responsible, in part, for apoptosis resulting from
deregulated c-myc expression and its loss in human breast
tumours may eliminate c-Myc’s potential tumour suppressive
role. In this study, bax-knockout and MMTV-c-myc transgenic
mice were mated to generate a mammary-relevant model in which
the influence of the loss of bax on c-Myc-induced apoptosis
and tumorigenesis could be investigated. Our results clearly
demonstrate that loss of bax is directly and significantly correlated
with a reduction in apoptosis in mammary adenocarcinomas.
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Figure 3 Apoptosis is significantly decreased in mammary adenocarci-
nomas from parous MMTV-c-myc transgenic/bax-knockout mice with loss
of each wild-type allele of bax. A trend toward decreased apoptosis, with
loss of allelic bax, is seen for mammary dysplastic lesions. Data are
presented as mean apoptotic index7s.e.m. and significance comparisons
were conducted by ANOVA and Scheffe post hoc testing: a (P¼0.001), b
(P¼0.033), c (P¼0.017), and d (P¼0.001). (Inset) Histological image of
TUNEL-stained mammary section with black arrowheads indicating
representative TUNEL-positive apoptotic cells.
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Figure 4 Cellular proliferation is not significantly altered, with loss of
allelic bax, in mammary adenocarcinomas and mammary dysplastic lesions
from parous MMTV-c-myc transgenic/bax-knockout mice. Cellular pro-
liferation is significantly increased in mammary adenocarcinomas as
compared to mammary dysplastic lesions within each genotype. Data are
presented as mean proliferative index7s.e.m. and significance comparisons
were conducted by ANOVA and Scheffe post hoc testing: a (P¼0.048), b
(P¼0.024), and c (P¼0.0001). (Inset) Histological image of HþE-stained
mammary section with black arrowhead indicating a representative mitotic
figure.
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expression, results in an elevation in mammary tumour multi-
plicity without influencing mammary tumour latency or histo-
pathology. However, in contradistinction to prior findings for
c-Myc-mediated lymphomagenesis (Eischen et al, 2001a), complete
loss of bax did not promote c-Myc-induced mammary tumorigen-
esis, suggesting that some amount of Bax expression is required for
mammary tumorigenesis.
Previous studies have reported the incidence of mammary
tumours in single strain, multiparous MMTV-c-myc mice as
approaching 100%; however, no studies of MMTV-c-myc trans-
genic or myc-containing bitransgenic mice have reported mam-
mary tumour multiplicity findings (Stewart et al, 1984; Jamerson
et al, 2000). In our study of multiparous, multistrain MMTV-c-myc
transgenic mice possessing both wild-type bax alleles, the
incidence of mammary tumours was 20% and the multiplicity
was one tumour per mouse. This reduced mammary tumour
incidence identified in our studies for c-myc transgenic mice may
reflect the tumour suppressive influences of a mixed-strain
background in our mouse model or may represent functional
changes in the genetic control of the c-myc transgene itself.
Significantly, other studies have concluded that alteration of or
mixing of inbred genetic backgrounds can significantly influence
transgene-induced mammary tumorigenesis (Griep et al, 1998;
Lifsted et al, 1998; Rowse et al, 1998; Le Voyer et al, 2000; Rose-
Hellekant et al, 2002). The C57BL/6 XFVB cross utilised in the
current study has been previously studied in this respect,
implicating C57BL/6 as bearing an unknown mammary tumour
penetrance-modifying influence (Rose-Hellekant et al, 2002).
Although the c-Myc penetrance-modifier in our study remains
unknown, methylation of the MMTV-LTR promotional element,
silencing of linked transgene expression, and abrogation of
transgene-dependent tumorigenesis has been described previously
(Mangues et al, 1995; Betzl et al, 1996; Zhou et al, 2001).
Additionally, MMTV-LTR methylation patterns are heterogeneous
among offspring from the same litter and promoter demethylation
appears to be required for transgene-driven tumorigenesis. The
reduced mammary tumour incidence in our study animals may
result from methylation of the MMTV-c-myc transgene and
concomitant reduction or elimination of c-Myc protein expression.
Analysis of c-Myc protein expression in mammary gland and
tumour lysates confirms that c-Myc expression is limited to the
mammary adenocarcinomas and is below the sensitivity of this
assay in the nontumorous mammary glands from c-myc transgene-
positive and transgene-negative mice. These data suggest that
functional changes in the genetic or epigenetic control of c-myc
transgene expression may be responsible for the diminished
penetrance of the mammary tumour phenotype in our studies.
Evaluation of mammary gland whole mounts from tumour-
bearing and nontumour-bearing study mice revealed a definite
correlation between the presence of multiple hyperplastic alveolar
nodules and the presence of c-myc transgene expression and
mammary adenocarcinomas. The absence of mammary gland
hyperplastic changes, as assessed by whole mount, in animals that
do not express the c-myc transgene lends credence to the idea that
the transforming influence of c-myc transgene expression is
required for hyperplastic, dysplastic, and neoplastic changes in
the mammary gland in this model. In tumour-bearing mice, the
presence of transgene-induced glandular changes at the whole
mount level is confirmed by the identification of mammary gland
dysplastic changes at the microscopic histopathological level. As
expected, and independent of the status of bax in our study mice, a
cribiform mammary adenocarcinoma phenotype was identified.
Evaluation of the mammary gland pathology of genetically
engineered mice has shown that the c-myc transgene-induced
adenocarcinomas are characterised by a cribiform phenotype that
is dominantly expressed when the c-myc transgene is co-expressed
with other transgenes (Cardiff et al, 2000). Therefore, our findings
revealed the transforming role of the c-myc transgene in our
tumour model and have suggested that expression of the cribiform
tumour phenotype is not abrogated by elimination of the bax
tumour suppressor gene.
As anticipated for an apoptosis-regulatory gene, loss of wild-type
bax alleles did not significantly alter proliferation, in both mammary
adenocarcinomas and dysplastic mammary tissue, in tumour-
bearing MMTV-c-myc mice. Our results did demonstrate a
significant increase in cellular proliferation between dysplastic
mammary tissues and mammary adenocarcinomas, as might be
expected in the progression of mammary lesions. As expected with
the loss of the proapoptotic bax gene, a trend toward diminished
apoptosis in dysplastic mammary tissue and a significant diminu-
tion in apoptosis in mammary adenocarcinomas was identified in
tumour-bearing MMTV-c-myc mice with loss of one and both wild-
type alleles of bax. Our studies also demonstrate that haploid loss of
bax is associated with an increase in mammary tumour multiplicity
in multiparous MMTV-c-myc study mice; intriguingly however,
complete loss of the wild-type bax alleles results in a mammary
tumour multiplicity, but not incidence identical to that for mice with
intact bax. These results, of bax loss influencing mammary gland
apoptosis and mammary tumour multiplicity, but not incidence, are
similar, but not identical, to those seen for the C(3)1/SV40-Tag/bax-
knockout mice (Shibata et al, 1999). Characterisation of bax-
hemizygous and bax-nullizygous mice expressing the C(3)1-Tag
transgene resolved that selectively in hemizygous bax animals,
apoptosis was significantly reduced in preneoplastic mammary
lesions with subsequent enhancement of tumour number (Shibata
et al, 1999). No such enhancement in SV40-dependent mammary
tumorigenesis was observed in bax-nullizygous mice. The reduc-
tions in c-Myc-mediated mammary tumour multiplicity and
incidence seen in our bax-nullizygous mice are similar to the
findings reported from this previous study and may reflect
mammary gland hypoplasia resulting from loss of both wild-type
alleles of bax (Shibata et al, 1999). It is worth considering that Bax
may have a stage-specific role in suppressing c-Myc-mediated
mammary tumorigenesis (apoptosis suppression with bax loss is
differentially stage-specific with respect to the inducer of apoptosis,
Myc or TAg). Notably, as indicated earlier in the introduction, Bax
loss strongly enhances c-Myc-dependent lymphomagenesis (Eischen
et al, 2001a). It should be noted that c-Myc-dependent lymphoma-
genesis is also strongly enhanced in the absence of one or both p53
alleleles, in contrast to mammary tumorigenesis. (Elson et al, 1995,
McCormack et al, 1998). Since c-Myc-dependent mammary
tumours seldom contain mutated p53, in striking contrast to
lymphomas, future studies could productively address the interac-
tions between p53 and Bax in distinguishing differential, c-Myc
effects on tumorigenesis in these two tissue types.
In conclusion, haploid loss of bax in multiparous MMTV-c-myc
transgenic mice is associated with a significantly decreased
mammary tumour apoptotic index. Loss of bax is not associated
with alterations in mammary tumour proliferation. Our results
indicate that bax is involved in the regulation of apoptosis in
tumours of the murine mammary gland and may be, at best, a
weakly negative modulator of c-Myc-mediated mammary tumor-
igenesis. Complete loss of bax, associated with the most significant
suppression of apoptosis in mammary tumours in our model, is
clearly not associated with suppression of mammary tumorigen-
esis, as compared with loss of one wild-type allele of bax. This
finding suggests that Bax may be required for mammary tumour
development at some stage, and that the contribution of other
apoptotic pathways may be important to mammary tumorigenesis
in our model. These results are the first published that
demonstrate that haploid loss of bax, as seen in many human
breast cancers, significantly reduces mammary tumour apoptosis
provoked by a human breast cancer-relevant proto-oncogene,
c-myc. Our results clearly show that in contrast to the role of
Bax as a proapoptotic tumour suppressor in c-Myc-induced
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mammary tumorigenesis Bax is proapoptotic, but lacking in
significant mammary tumour suppressive activity.
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